Pete Sessions
Trade Performance Intelligence
Score: 8/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
4 flagsRep. Sessions sold $15,001-$50,000 in $JNJ on 2025-06-12 — 35 days before HR4528 ("Price Gouging Prevention Act of 2025") was introduced, a bill that could limit corporate profitability for large-cap companies.
Rep. Sessions sold $15,001-$50,000 in $JNJ on 2025-06-12 — 41 days before HR4668 ("End the Vaccine Carveout Act") was introduced, a bill that removes liability protections for vaccine manufacturers.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act mandates no-cost coverage for HIV prevention drugs and related services, directly increasing demand for these medications and associated diagnostic tests. This legislation creates a guaranteed market expansion for pharmaceutical companies producing PrEP/PEP drugs and diagnostic providers, while increasing costs for health insurers.
Treat and Reduce Obesity Act of 2025
The Treat and Reduce Obesity Act of 2025 (S.1973) is in early legislative stages, aiming to expand Medicare coverage for obesity treatments, including GLP-1 agonists and intensive behavioral therapy. This bill, if enacted, would significantly increase the total addressable market for pharmaceutical companies producing obesity drugs and manufacturers of related medical devices. Companies like Eli Lilly and Company ($LLY) and Novo Nordisk A/S ($NVO) are positioned to benefit from this potential market expansion.
Biosimilar Red Tape Elimination Act
The Biosimilar Red Tape Elimination Act, HR5526, if enacted, would automatically grant interchangeability to biosimilar products, reducing market exclusivity for innovator biologic manufacturers. This bill is in the early stages, having been referred to the House Committee on Energy and Commerce on September 19, 2025. Innovator biologic manufacturers like Amgen, Johnson & Johnson, and Biogen face potential market share erosion, while biosimilar producers like Viatris and Teva could benefit.
End the Vaccine Carveout Act
The 'End the Vaccine Carveout Act' removes liability protections for vaccine manufacturers, directly increasing their legal and operational risks. This bill, if enacted, will significantly alter the risk profile and profitability of pharmaceutical companies producing vaccines. Companies like Pfizer, Moderna, GSK, and Johnson & Johnson face increased litigation exposure.
Medical Research for Our Troops Act
The 'Medical Research for Our Troops Act' (HR3906) proposes to restore $1.181 billion to the Defense Health Agency for military health R&D. This bill is in the early stages, having been referred to the House Committee on Appropriations on June 11, 2025. Companies with defense contracts in clinical research, medical devices, and pharmaceuticals would benefit if this funding is restored.
Price Gouging Prevention Act of 2025
The Price Gouging Prevention Act of 2025 directly limits corporate profitability for large-cap companies during 'exceptional market shock' events by mandating pre-shock margin maintenance. This legislation increases regulatory risk and caps potential upside for companies with significant market power across all sectors, leading to decreased profitability during crises. All major corporations face reduced profit potential and increased compliance costs.
Protecting Free Vaccines Act of 2025
The 'Protecting Free Vaccines Act of 2025' (S.2857) is in the early stages, having been referred to committee. This bill aims to codify existing mandates for ACIP-recommended immunization coverage, ensuring stable revenue for vaccine manufacturers and health insurers by preventing future disruptions to current vaccine coverage. It does not introduce new market drivers or significant changes to demand.
Medicare for All Act
The Medicare for All Act (HR3069) has been introduced in the House and referred to seven committees. This bill proposes a national health insurance program that would eliminate private health insurance and shift all healthcare spending to the federal government, directly impacting the business models of private health insurers and potentially reducing pricing power for pharmaceutical and medical device companies. Despite the bill's early stage, its comprehensive scope represents a significant long-term risk to the healthcare sector.
Protecting Free Vaccines Act
The 'Protecting Free Vaccines Act' (HR5448) is an early-stage bill that, if enacted, would mandate no-cost coverage for ACIP-recommended vaccines by Medicare, Medicaid, CHIP, and private insurers until January 1, 2030. This would directly increase demand for vaccine manufacturers and shift cost burdens to health insurers and government programs. Vaccine manufacturers are positioned for sustained revenue growth, while health insurers face increased costs.
Ensuring Patient Access to Critical Breakthrough Products Act
The 'Ensuring Patient Access to Critical Breakthrough Products Act' (HR5343) has advanced out of committee, indicating significant legislative momentum for expedited Medicare coverage of FDA-designated breakthrough medical devices. This bill directly benefits manufacturers by removing a key barrier to market adoption and revenue generation. Companies like Medtronic, Intuitive Surgical, Abbott Laboratories, Johnson & Johnson, and Becton, Dickinson and Company are positioned to gain from this accelerated market access.
Live Charts
Other Filings by Pete Sessions
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.